The Medicines Company (MDCO), Merck & Co., Inc. (MRK), Baxter International Inc. (BAX): Three Reasons to Like This Critical Care Company

Page 1 of 2

The Medicines Company (NASDAQ:MDCO) is a mid-cap value stock that jumped by 21% in the last 12 months, trading at a 52-week price range of $20.04-$37.40. This is backed by strong performance and significant sales growth in marketed products such as anticoagulants. Essentially, the company provides medical solutions for the treatment of critical care patients in hospitals. I consider this an investment-grade company based on the following factors:

Solid portfolio with wide range of products and product candidates

Opportunity in highly competitive critical care and anticoagulant markets

Sales growth driving positive performance

The Medicines Company

Diversified portfolio
The company has three marketed products and five in different development stages. Importantly, all of them are focused on critical care therapeutics, which creates technology depth for the company. The marketed products in the U.S. include Angiomax, Cleviprex, and Argatroban.

: Angiomax injection, an anticoagulant agent, is used to prevent the formation of blood clots that lead to heart attack or stroke.

: Used as an anticoagulant in adult patients.

: Indicated for the reduction of blood pressure when oral therapy is not feasible.

Moreover, the pipeline includes a variety of product candidates. Of them, three products — cangrelor, oritavancin and MDCO-157 — are in advanced stages, and two — MDCO-2010 and MDCO-216 — are in early stages of development. The company also has a portfolio of generic products used for acute care. In addition, it co-partners with AstraZeneca to market the oral antiplatelet drug Brilinta in the U.S. and with Bristol-Myers Squibb for Recothrom in the global market. Recothrom is a surgical hemostat that is applied topically during surgery to stop bleeding.

Opportunity in anticoagulant and critical care therapeutics markets
More than 5 million patients are admitted to American intensive care units annually, primarily for critical medical conditions including respiratory failure, postoperative management, stroke and heart failure. Increasingly, infants and the older population are getting admitted. According to GBI Research estimates, the overall critical care therapeutics market value is expected to grow at a compounded annual growth rate of 5% to reach $3.2 billion in 2019. The growth is largely driven by increasing demand of existing products, and approval and launches of new products.

The anticoagulant therapies market is large, and competition is very intense due to the incidence and severity of cardiovascular diseases. There are a number of anticoagulant therapies currently available in the market. New products such as oral anticoagulants are also in many pipelines. MarketResearch also estimates that the U.S. anticoagulants market will grow from $7.06 billion in 2012 to $15.32 billion in 2019. The Medicines Company (NASDAQ:MDCO) focuses mostly on the U.S. market and generates more than 90% of revenues from the U.S. Assuming even a 2% market share for its candidate product Angiomax, market opportunity for the company in the anticoagulant market will be around $170-$200 million by 2015.

Position among peers
Angiomax competes primarily with Eli Lilly’s ReoPro and Integrilin from Merck & Co., Inc. (NYSE:MRK). Integrilin is a platelet aggregation inhibitor indicated for the treatment of acute coronary syndrome and percutaneous coronary intervention. The product is losing its sales quarterly, possibly due to advent of new drugs and generic products. It is expected to decrease further in coming quarters. In the second quarter of 2013, Merck & Co., Inc. (NYSE:MRK)’s sales were down by 7% to $11 billion, and adjusted net income also decreased by 24% to $2.5 billion, or $0.84 per share, compared to same period last year. I suspect that this trend will continue for the next quarter.

Page 1 of 2
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!